A candidate therapeutic vaccine for chronic hepatitis C infection based on envelope 1 protein: Tolerability and immunogenicity in healthy adult volunteers.

被引：0
|
作者：
Leroux-Roels, GG
Depla, E
Hulstaert, F
De Smedt, J
Desombere, I
Maertens, G
机构：
[1] State Univ Ghent, B-9000 Ghent, Belgium
[2] Innogenetics, Ghent, Belgium
[3] Regipharm, Brussels, Belgium
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1110
引用
收藏
页码：449A / 449A
页数：1
相关论文
共 50 条
  • [21] EVALUATION OF THE TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORALLY ADMINISTERED DWP05195, A NEW TRPV1 ANTAGONIST IN HEALTHY ADULT MALE VOLUNTEERS.
    Lee, S.
    Jiang, F.
    Lee, J.
    Chung, J.
    Jang, I.
    Lee, H.
    Yu, K.
    Jang, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S77 - S77
  • [22] Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection
    Guan, Xiao-duo
    Tang, Xian-ge
    Zhang, Ying-jun
    Xie, Hong-ming
    Luo, Lin
    Wu, Dan
    Chen, Rui
    Hu, Pei
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [23] A phase 1 vaccine trial with recombinant parvovirus B19 virus-like particles in seronegative healthy adult volunteers.
    Connor, E
    FolenaWasserman, G
    Alfonso, C
    Bowen, S
    Kajigaya, S
    Tsao, E
    Oliver, C
    Schenerman, M
    Anderson, S
    Top, FH
    Young, NS
    BLOOD, 1995, 86 (10) : 528 - 528
  • [24] Immunogenicity of hepatitis B vaccine in multi-transfused thalassemic patients with and without hepatitis C infection: A comparative study with healthy controls
    Froutan-Pishbijari, H
    Ghofrani, H
    Mirmomen, S
    Kazemi-Asi, S
    Nassiri-Toosi, M
    Farahvash, MJ
    Toroghi, HH
    Aminian, K
    Mansour-Ghanaei, F
    Bagherzadeh, AH
    MEDICAL SCIENCE MONITOR, 2004, 10 (12): : CR679 - CR683
  • [25] Characterization of hypervariable region in hepatitis C virus envelope protein during acute and chronic infection
    Higashi, K
    Tsukiyama-Kohara, K
    Tanaka, T
    Tanaka, E
    Kiyosawa, K
    Kohara, M
    ARCHIVES OF VIROLOGY, 2005, 150 (05) : 883 - 898
  • [26] Characterization of hypervariable region in hepatitis C virus envelope protein during acute and chronic infection
    K. Higashi
    K. Tsukiyama-Kohara
    T. Tanaka
    E. Tanaka
    K. Kiyosawa
    M. Kohara
    Archives of Virology, 2005, 150 : 883 - 898
  • [27] Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study
    Pastural, Elodie
    McNeil, Shelly A.
    MacKinnon-Cameron, Donna
    Ye, Lingyun
    Langley, Joanne M.
    Stewart, Robert
    Martin, Luis H.
    Hurley, Gregory J.
    Salehi, Sanaz
    Penfound, Thomas A.
    Halperin, Scott
    Dale, James B.
    VACCINE, 2020, 38 (06) : 1384 - 1392
  • [28] Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study
    Daryani, Naser Ebrahimi
    Nassiri-Toosi, Mohsen
    Rashidi, Armin
    Khodarahmi, Iman
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (02) : 294 - 298
  • [29] Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection:A case-control study
    Naser Ebrahimi Daryani
    Mohsen Nassiri-Toosi
    Armin Rashidi
    Iman Khodarahmi
    World Journal of Gastroenterology, 2007, (02) : 294 - 298
  • [30] Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection
    Zabaleta, Aintzane
    D'Avola, Delia
    Echeverria, Itziar
    Llopiz, Diana
    Silva, Leyre
    Villanueva, Lorea
    Ignacio Riezu-Boj, Jose
    Larrea, Esther
    Pereboev, Alexander
    Jose Lasarte, Juan
    Rodriguez-Lago, Iago
    Inarrairaegui, Mercedes
    Sangro, Bruno
    Prieto, Jesus
    Sarobe, Pablo
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2015, 2 : 15006
12345